Lucy Scientific Discovery, an early-stage psychotropics contract manufacturing company, raised $7.5 million by offering 1.9 million shares at $4.00. It previously planned to offer 2.0 million shares at that price
Lucy Scientific Discovery has a Controlled Substances Dealer’s License from Health Canada to produce and conduct research using psilocybin, psilocin, MDMA, and LSD. The early stage company aims to achieve production-scale manufacturing capabilities and cGMP certification by June 2023.
The Victoria, Canada-based company plans to list on the Nasdaq under the symbol LSDI. WestPark Capital acted as sole bookrunner on the deal.
